Pain in the early stages of orthodontic treatment.

M. Jones,C. Chan

1992-05-01

Abstract:

What problem does this paper attempt to address?

High-Throughput Screening Platform for the Discovery of New Immunomodulator Molecules from Natural Product Extract Libraries

José Pérez del Palacio,Caridad Díaz,Mercedes de la Cruz,Frederick Annang,Jesús Martín,Ignacio Pérez-Victoria,Víctor González-Menéndez,Nuria de Pedro,José R. Tormo,Francesca Algieri,Alba Rodriguez-Nogales,M. Elena Rodríguez-Cabezas,Fernando Reyes,Olga Genilloud,Francisca Vicente,Julio Gálvez

DOI: https://doi.org/10.1177/1087057116635517

IF: 3.341

2016-07-01

SLAS DISCOVERY

Abstract:It is widely accepted that central nervous system inflammation and systemic inflammation play a significant role in the progression of chronic neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, neurotropic viral infections, stroke, paraneoplastic disorders, traumatic brain injury, and multiple sclerosis. Therefore, it seems reasonable to propose that the use of anti-inflammatory drugs might diminish the cumulative effects of inflammation. Indeed, some epidemiological studies suggest that sustained use of anti-inflammatory drugs may prevent or slow down the progression of neurodegenerative diseases. However, the anti-inflammatory drugs and biologics used clinically have the disadvantage of causing side effects and a high cost of treatment. Alternatively, natural products offer great potential for the identification and development of bioactive lead compounds into drugs for treating inflammatory diseases with an improved safety profile. In this work, we present a validated high-throughput screening approach in 96-well plate format for the discovery of new molecules with anti-inflammatory/immunomodulatory activity. The in vitro models are based on the quantitation of nitrite levels in RAW264.7 murine macrophages and interleukin-8 in Caco-2 cells. We have used this platform in a pilot project to screen a subset of 5976 noncytotoxic crude microbial extracts from the MEDINA microbial natural product collection. To our knowledge, this is the first report on an high-throughput screening of microbial natural product extracts for the discovery of immunomodulators.

biochemical research methods,biotechnology & applied microbiology,chemistry, analytical
Data-driven discovery of innate immunomodulators via machine learning-guided high throughput screening

Yifeng Tang,Jeremiah Kim,Carman KM IP,Azadeh Bahmani,Qing Chen,Matthew G Rosenberger,Aaron Palmer Esser-Kahn,Andrew L Ferguson

DOI: https://doi.org/10.1039/d3sc03613h

IF: 8.4

2023-10-20

Chemical Science

Abstract:The innate immune response is vital for the success of prophylactic vaccines and immunotherapies. Control of signaling in innate immune pathways can improve prophylactic vaccines by inhibiting unfavorable systemic inflammation and immunotherapies by enhancing immune stimulation. In this work, we developed a machine learning-enabled active learning pipeline to guide in vitro experimental screening and discovery of small molecule immunomodulators that improve immune responses by altering the signaling activity of innate immune responses stimulated by traditional pattern recognition receptor agonists. Molecules were tested by in vitro high throughput screening (HTS) where we measured modulation of the nuclear factor κ-light-chain-enhancer of activated B-cells (NF-κB) and the interferon regulatory factors (IRF) pathways. These data were used to train data-driven predictive models linking molecular structure to modulation of the NF-κB and IRF responses using deep representational learning, Gaussian process regression, and Bayesian optimization. By interleaving successive rounds of model training and in vitro HTS, we performed an active learning-guided traversal of a 139,998 molecule library. After sampling only ∼2% of the library, we discovered viable molecules with unprecedented immunomodulatory capacity, including those capable of suppressing NF-κB activity by up to 15-fold, elevating NF-κB activity by up to 5-fold, and elevating IRF activity by up to 6-fold. We extracted chemical design rules identifying particular chemical fragments as principal drivers of specific immunomodulation behaviors. We validated the immunomodulatory effect of a subset of our top candidates by measuring cytokine release profiles. Of these, one molecule induced a 3-fold enhancement in IFN-β production when delivered with a cyclic di-nucleotide stimulator of interferon genes (STING) agonist. In sum, our machine learning-enabled screening approach presents an efficient immunomodulator discovery pipeline that has furnished a library of novel small molecules with a strong capacity to enhance or suppress innate immune signaling pathways to shape and improve prophylactic vaccination and immunotherapies.

chemistry, multidisciplinary
Immune cell screening of a nanoparticle library improves atherosclerosis therapy

Jun Tang,Samantha Baxter,Arjun Menon,Amr Alaarg,Brenda L. Sanchez-Gaytan,Francois Fay,Yiming Zhao,Mireille Ouimet,Mounia S. Braza,Valerie A. Longo,Dalya Abdel-Atti,Raphael Duivenvoorden,Claudia Calcagno,Gert Storm,Sotirios Tsimikas,Kathryn J. Moore,Filip K. Swirski,Matthias Nahrendorf,Edward A. Fisher,Carlos Pérez-Medina,Zahi A. Fayad,Thomas Reiner,Willem J. M. Mulder

DOI: https://doi.org/10.1073/pnas.1609629113

IF: 11.1

2016-10-17

Proceedings of the National Academy of Sciences

Abstract:Significance The immune system plays an essential role in the pathophysiology of major diseases such as atherosclerosis, diabetes, and cancer, which has inspired the development of numerous small molecules to modulate immune cells, intending to create immunotherapies for these diseases. Tissue- and cell-specific delivery of these small molecules is the key to transform these compounds to safe, potent immunotherapies. In this study, we present an in vivo nanoparticle screen approach that involves designing and evaluating a library of nanoparticles with distinct immune cell targeting specificity. This study carries out a systematic in vivo immune cell screening to create effective nanoparticle-based immunotherapy for modulating the pathological immune cells in atherosclerosis.
Alterations in intracellular calcium during sepsis.

J. Bhattacharyya,M. Sayeed

1997-10-01

Indian Journal of Physiology and Pharmacology

Abstract:Tissue injury and/or infection produce significant alterations in intracellular calcium ion regulation. These alterations in cellular calcium has recently been studied following both short term and long term septic model which uses two types of gram-negative bacteria frequently encountered human abdominal sepsis. Changes in calcium flux as well as functional disturbances has been observed in the major organs, specially in skeletal muscle. The changes in calcium flux in different organs were studied using 45Ca exchange, 19F NMR study or by using calcium-fluorescence probes. Calcium-channel blockers attenuate the increased effects of calcium flux. Further anti-cytokines may be useful to prevent septic injury in tissues.
Using systems medicine to identify a therapeutic agent with potential for repurposing in inflammatory bowel disease

Katie Lloyd,Stamatia Papoutsopoulou,Emily Smith,Philip Stegmaier,Francois Bergey,Lorna Morris,Madeleine Kittner,Hazel England,Dave Spiller,Mike H R White,Carrie A Duckworth,Barry J Campbell,Vladimir Poroikov,Vitor A P Martins Dos Santos,Alexander Kel,Werner Muller,D Mark Pritchard,Chris Probert,Michael D Burkitt,SysmedIBD Consortium

DOI: https://doi.org/10.1242/dmm.044040

2020-11-27

Abstract:Inflammatory bowel diseases (IBDs) cause significant morbidity and mortality. Aberrant NF-κB signalling is strongly associated with these conditions, and several established drugs influence the NF-κB signalling network to exert their effect. This study aimed to identify drugs that alter NF-κB signalling and could be repositioned for use in IBD. The SysmedIBD Consortium established a novel drug-repurposing pipeline based on a combination of in silico drug discovery and biological assays targeted at demonstrating an impact on NF-κB signalling, and a murine model of IBD. The drug discovery algorithm identified several drugs already established in IBD, including corticosteroids. The highest-ranked drug was the macrolide antibiotic clarithromycin, which has previously been reported to have anti-inflammatory effects in aseptic conditions. The effects of clarithromycin effects were validated in several experiments: it influenced NF-κB-mediated transcription in murine peritoneal macrophages and intestinal enteroids; it suppressed NF-κB protein shuttling in murine reporter enteroids; it suppressed NF-κB (p65) DNA binding in the small intestine of mice exposed to lipopolysaccharide; and it reduced the severity of dextran sulphate sodium-induced colitis in C57BL/6 mice. Clarithromycin also suppressed NF-κB (p65) nuclear translocation in human intestinal enteroids. These findings demonstrate that in silico drug repositioning algorithms can viably be allied to laboratory validation assays in the context of IBD, and that further clinical assessment of clarithromycin in the management of IBD is required.This article has an associated First Person interview with the joint first authors of the paper.
High-throughput screening identification of novel immunomodulatory combinations for the generation of tolerogenic dendritic cells

Sihan Jia,Jeremiah Kim,Aaron Palmer Esser-Kahn,Peter Deak

DOI: https://doi.org/10.3389/fmed.2023.1298424

IF: 3.9

2024-01-05

Frontiers in Medicine

Abstract:Introduction Tolerogenic Dendritic Cells (tolDCs) have an exceptional promise as a potential therapy for autoimmune disease and transplantation rejection. TolDCs are a unique phenotype of antigen presenting cells (APCs) that can influence naïve T cells into antigen specific T regulatory cells (T regs ), which can re-establish tolerance against auto/allo-antigens in the long term. Despite their promise, tolDCs have not found clinical success. Most strategies seek to generate tolDCs ex vivo by differentiating naïve dendritic cells (DCs) with immunosuppressive agents. Recently, we developed a tolDC generation strategy, which we call Push/Pull Immunomodulation (PPI). In PPI, DCs are treated with combinations of toll-like-receptor (TLR) agonists and immunomodulatory agents, which generate more robust, T reg -inducing tolDCs than previous strategies. Here, we seek to identify more potent and clinically viable PPI formulations using data from a high-throughput screening project. Methods Over 40,000 combinations of pathogen-associated molecular patterns (PAMPs) and immunomodulatory small molecules were screened using a modified murine macrophage line, RAW dual cells, to observe the effect of these combinations on two major immune regulatory transcription factors, NF-κB and IRF. Combinations were further screened for inflammatory cytokine activity using a human monocyte cell line, THP-1, then on murine DCs. Leading candidates were co-cultured with T cells to assess antigen specific T cell responses. Results From this data, we identified 355 combinations that showed low or moderate IRF activity, low NF-κB activity, low inflammatory cytokine generation and good viability: all hallmarks of tolerogenic potential. We further screened these 355 combinations using bone marrow derived DCs (BMDCs) and identified 10 combinations that demonstrated high IL-10 (tolerogenic) and low TNF-α (inflammatory) secretion. After further optimizing these combinations, we identified two combinations that generate robust tolDCs from BMDCs ex vivo . We further show that these PPI-tolDCs can also generate antigen specific T regs but do not increase overall T reg populations. Discussion These second-generation PPI formulations have significant potential to generate robust tolDCs and strong antigen specific T regs .

medicine, general & internal
Abstract 2944: A high-throughput screening system for identifying therapeutic targets in immuno-oncology

Dippal Parikh,Soon Youn Choi,Ki Eun Pyo,Hong-Pyo Lee,Kyuho Han

DOI: https://doi.org/10.1158/1538-7445.am2024-2944

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract INTRODUCTION: Over the last decade, cancer immunotherapy has revolutionized cancer treatment. However, more than half of patients don’t respond, and responders often lack lasting effects. Understanding how genetic variants in cancer cells influence their interaction with immune cells, especially T cells, is crucial to uncover underlying mechanisms. Genetic screens are powerful for uncovering responsible genes for various phenotypes, but challenges in obtaining ample samples to set up a proper immune and cancer co-culture system have limited their use for identifying immune modulators in cancer: primary mouse T cells expressing CD3 against a specific antigen (typically albumin) need to be extracted from transgenic mice and only syngeneic mouse cancer cell lines that match these T cells can be paired, restricting the utilization of human T cells and human cancer cells for this co-culture screening setup. METHODS: Here, we present a highly scalable co-culture system that enables genome-wide CRISPR screens on a pair of human primary T cells and any allogeneic human cancer cell lines. This system utilizes the expression of a membrane-targeted protein in mammalian cells, named as ImBridge, which directly engages and activates CD3+ immune cells. This mechanism bypasses the need for matched MHC on target cancer cells. RESULTS: We validated activation of CD3+ immune cells and selective cancer cell cytotoxicity by ImBridge. A genome-scale CRISPR screen utilizing the co-culture system unveiled known immune-oncology targets including PD-L1 and PTPN2 and revealed MEDiC_01 as a novel therapeutic target. Genetic loss of MEDiC_01 in cancer cells significantly sensitized them to cytotoxic cells, effectively eliminating cancers in the presence of human PBMCs. CONCLUSION: We demonstrated a scalable and efficient approach for conducting high-throughput functional screens to uncover genes that modulate interactions between effector T cells and target cancer cells. This can facilitate the identification of new immuno-oncology therapeutic targets, insights into underlying mechanisms, and genetic factors influencing immune susceptibility and evasion. Citation Format: Dippal Parikh, Soon Youn Choi, Ki Eun Pyo, Hong-Pyo Lee, Kyuho Han. A high-throughput screening system for identifying therapeutic targets in immuno-oncology [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2944.

oncology
Evaluating immune response in vitro in a relevant microenvironment: a high-throughput microfluidic model for clinical screening

Flora Doffe,Layla Fuoco,Judith Michels,Sandra Jernström,Raphael Tomasi,Pierre Savagner

DOI: https://doi.org/10.37349/etat.2022.00117

2022-12-29

Exploration of Targeted Anti-tumor Therapy

Abstract:Aim: Functional screening of new pharmaceutical compounds requires clinically relevant models to monitor essential cellular and immune responses during cancer progression, with or without treatment. Beyond survival, the emergence of resistant tumor cell clones should also be considered, including specific properties related to plasticity, such as invasiveness, stemness, escape from programmed cell death, and immune response. Numerous pathways are involved in these processes. Defining the relevant ones in the context of a specific tumor type will be key to designing an appropriate combination of inhibitors. However, the diversity and potential redundancy of these pathways remain a challenge for therapy. Methods: A new microfluidic device developed by Okomera was dedicated to the screening of drug treatment for breast cancer. This microchip includes 150 droplet-trapping microwells, offering multi-chip settings and multiple treatment choices. Results: After validating the system with established cell lines and a panel of drugs used clinically at Gustave Roussy, preclinical experiments were initiated including patient-derived xenograft (PDX) and primary tumor cells-derived tumoroids with the collaboration of Gustave Roussy clinicians. Tumor-isolated lymphocytes were also added to the tumoroids, using secondary droplets in proof-of-concept experiments. Conclusions: These results show the relevance of the methodology for screening large numbers of drugs, a wide range of doses, and multiple drug combinations. This methodology will be used for two purposes: 1) new drug screening from the compound library, using the high throughput potential of the chip; and 2) pre-clinical assay for a two-weeks response for personalized medicine, allowing evaluation of drug combinations to flag an optimized treatment with potential clinical application.
A Computer Screening Approach to Immunoglobulin Superfamily Structures and Interactions: Discovery of Small Non-Peptidic CD4 Inhibitors As Novel Immunotherapeutics.

S Li,JM Gao,T Satoh,TM Friedman,AE Edling,U Koch,S Choksi,XB Han,R Korngold,ZW Huang

DOI: https://doi.org/10.1073/pnas.94.1.73

2005-01-01

Abstract:The interaction between CD4 and major histocompatibility complex (MHC) class II proteins is critical for the activation of CD4+ T cells, which are involved in transplantation reactions and a number of autoimmune diseases. In this study we have identified a CD4 surface pocket as a functional epitope implicated in CD4-MHC class II interaction and T-cell activation. A computer-based strategy has been used to screen approximately 150,000 non-peptidic organic compounds in a molecular data base and to identify a group of compounds as ligands of the proposed CD4 surface pocket. These small organic compounds have been shown to specifically block stable CD4-MHC class II binding, and exhibit significant inhibition of immune responses in animal models of autoimmune disease and allograft transplant rejection, suggesting their potential as novel immunosuppressants. This structure-based computer screening approach may have general implications for studying many immunoglobulin-like structures and interactions that share similar structural features. Furthermore, the results from this study have demonstrated that the rational design of small non-peptidic inhibitors of large protein-protein interfaces may indeed be an achievable goal.
Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis

Arthur Petitdemange,Julien Blaess,Jean Sibilia,Renaud Felten,Laurent Arnaud

DOI: https://doi.org/10.1177/1759720X20969261

2020-12-16

Abstract:Background: Pathogenic inflammatory pathways are largely shared between different autoimmune and inflammatory diseases (AIDs). This offers the potential to develop a given targeted therapy in several AIDs. Methods: We analyzed two clinical trials registries (ClinicalTrials.gov and EU Clinical Trials Register) to identify the targeted therapies whose development is shared between at least two of the most common AIDs [rheumatoid arthritis (RA), spondyloarthritis (SpA), cutaneous psoriasis (cPso), inflammatory bowel diseases (IBD), systemic lupus erythematosus (SLE), primary Sjögren's syndrome (pSS), systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), giant cell arteritis (GCA), and multiple sclerosis (MS)] using an in-depth repurposing analysis. Results: We identified 142 shared targeted therapies. The four diseases in which shared targeted therapies were the most numerous were RA (n = 92), cPso (n = 67), IBD (n = 58), and SLE (n = 56). The two clusters of diseases between which the overlap of targeted therapies was the most important were RA and SLE as well as RA, SpA, cPso, and IBD. The targeted therapies which were shared by five diseases or more were abatacept, ustekinumab, rituximab, anakinra, etanercept, infliximab, secukinumab, tofacitinib, alemtuzumab, tocilizumab, adalimumab, apremilast, baricitinib, belimumab, brodalumab, filgotinib, and upadacitinib. The most frequently targeted molecules and pathways were (by descending frequency): JAK-STAT pathways, Th17 axis, TNF-α, IL-6, costimulation molecules, BAFF, CD20, BTK, chemokines and integrins, IL-1, and type I interferon. Conclusion: Many targeted therapies are developed in several AIDs, reflecting the overlap of pathogenic pathways and potential of drug repurposing. This suggests that a revision of the current, clinically based classification of AIDs towards a more mechanistic-based taxonomy might be relevant.
HLA-DR4 restricted lymphocyte proliferation to a Mycobacterium tuberculosis extract in rheumatoid arthritis and healthy subjects.

A. Palacios-Boix,I. Estrada-G,M. Colston,G. Panayi

DOI: https://doi.org/10.4049/jimmunol.140.6.1844

1988-03-15

Abstract:The ability of an antigenic extract of Mycobacterium tuberculosis to induce proliferation of PMBC from rheumatoid arthritis (RA) patients and normal controls was examined. The subjects were further classified as bearing or not bearing the HLA-DR4 phenotype, since this specificity is regarded as a genetic determinant commonly associated with RA. The mycobacterial extract induced significantly higher proliferative responses in lymphocytes from all HLA-DR4 positive as compared to HLA-DR4 negative subjects regardless of whether they had RA or not. This response was maximal at day 6 of incubation and could be abrogated by anti-DR/DQ mAb added to the culture. SDS-PAGE of this extract revealed three major protein bands located at Mr 14, 47, and 65 kDa. After fractionation, Western blotting, and resuspension of protein-laden nitrocellulose particles, only the 14- and 47-kDa proteins retained the original proliferative capacity of the mycobacterial extract. The band separating with a Mr of 47 kDa was found to be the most strongly associated with the HLA-DR4 restricted lymphocyte proliferation, and represents a newly identified M. tuberculosis Ag of relevance in T cell responses. These data provide insight into the pathogenic potential of certain bacterial Ag which could trigger or perpetuate inflammatory disorders when presented in the appropriate genetical background.
In silico Analyses of Immune System Protein Interactome Network, Single-Cell RNA Sequencing of Human Tissues, and Artificial Neural Networks Reveal Potential Therapeutic Targets for Drug Repurposing Against COVID-19

Andrés López-Cortés,Patricia Guevara-Ramírez,Nikolaos C. Kyriakidis,Carlos Barba-Ostria,Ángela León Cáceres,Santiago Guerrero,Esteban Ortiz-Prado,Cristian R. Munteanu,Eduardo Tejera,Doménica Cevallos-Robalino,Ana María Gómez-Jaramillo,Katherine Simbaña-Rivera,Adriana Granizo-Martínez,Gabriela Pérez-M,Silvana Moreno,Jennyfer M. García-Cárdenas,Ana Karina Zambrano,Yunierkis Pérez-Castillo,Alejandro Cabrera-Andrade,Lourdes Puig San Andrés,Carolina Proaño-Castro,Jhommara Bautista,Andreina Quevedo,Nelson Varela,Luis Abel Quiñones,César Paz-y-Miño

DOI: https://doi.org/10.3389/fphar.2021.598925

IF: 5.6

2021-02-26

Frontiers in Pharmacology

Abstract:Background: There is pressing urgency to identify therapeutic targets and drugs that allow treating COVID-19 patients effectively. Methods: We performed in silico analyses of immune system protein interactome network, single-cell RNA sequencing of human tissues, and artificial neural networks to reveal potential therapeutic targets for drug repurposing against COVID-19. Results: We screened 1,584 high-confidence immune system proteins in ACE2 and TMPRSS2 co-expressing cells, finding 25 potential therapeutic targets significantly overexpressed in nasal goblet secretory cells, lung type II pneumocytes, and ileal absorptive enterocytes of patients with several immunopathologies. Then, we performed fully connected deep neural networks to find the best multitask classification model to predict the activity of 10,672 drugs, obtaining several approved drugs, compounds under investigation, and experimental compounds with the highest area under the receiver operating characteristics. Conclusion: After being effectively analyzed in clinical trials, these drugs can be considered for treatment of severe COVID-19 patients. Scripts can be downloaded at https://github.com/muntisa/immuno-drug-repurposing-COVID-19 .

pharmacology & pharmacy
A novel bioinformatics pipeline for the identification of immune inhibitory receptors as potential therapeutic targets

Akashdip Singh,Alberto Miranda Bedate,Helen J Von Richthofen,Saskia V Vijver,Michiel van der Vlist,Raphael Kuhn,Alexander Yermanos,Jürgen JHE Kuball,Can Kesmir,M. Ines Pascoal Ramos,Linde Meyaard

DOI: https://doi.org/10.1101/2023.10.24.563834

2024-06-12

Abstract:Blocking inhibitory receptors like PD-1 and CTLA-4 has revolutionized cancer treatment in recent years. However, despite major successes in melanoma and lung cancer, the majority of cancer types are not responsive to these immunotherapies. As such, there is an ongoing need for the identification of novel inhibitory receptors as drug targets. Most inhibitory receptors signal via immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and previous studies have estimated that our genome contains over 1600 ITIM-bearing transmembrane proteins. However, further testing and development of this large number of candidates requires increased understanding of their expression patterns and likelihood to function as inhibitory receptor. To assist in the selection of novel inhibitory receptor as therapeutic targets, we designed a novel bioinformatics pipeline integrating machine learning-guided structural predictions and sequence-based likelihood models to identify 51 known and 390 putative inhibitory receptors. Using publicly available transcriptomics data of immune cells, we determined the expression of these novel inhibitory receptors, and classified them into previously proposed functional categories. Known and putative inhibitory receptors were expressed across a wide variety of immune cells, and we found cell type-specific patterns in expression of these receptors. We used our pipeline to study inhibitory receptor expression patterns in single cell transcriptomics data of tumour infiltrating T cells. We determined that putative immune inhibitory receptors were expressed differentially in CD4 and CD8 T cell subsets, including exhausted CD8 T cells and CD4 memory T cells, which could allow for subset-specific targeting. In conclusion, we present an inhibitory receptor pipeline that identifies 51 known and 390 novel inhibitory receptors. This pipeline will support future drug target selection across diseases where therapeutic targeting of immune inhibitory receptors is warranted.

Immunology
High-throughput screening and in vitro evaluation of CSB-0914; a novel small molecule NF-κB inhibitor attenuating inflammatory responses through NF-κB, Nrf2 and HO-1 cross-talk

Mesfer Al Shahrani,Mohammad AboHassan,Reem Gahtani,Mohammad Y Alshahrani,Muath Suliman,Irfan Ahmad,Mohd Saeed

DOI: https://doi.org/10.1080/07391102.2023.2294377

2023-12-21

Abstract:Unpleasant side effects of standard inflammatory drugs urges search for novel therapeutic candidates. This study aims in identifying novel anti-inflammatory NF-κB inhibitor by high-throughput computational and in-vitro pre-clinical approaches. Lead candidate selection was conducted by the use of computational docking molecular-dynamic simulations. The RBL-2H3 cell line, derived from rat basophils, was used to evaluate the release of cytokines and degranulation. The study focused on the study of neutrophil elastase and its role in cellular motility. Flow cytometry was utilized to evaluate the activation of basophils and the expression of critical signaling proteins. High throughput screening identified CSB-0914 to stably bind NF-κB-p50 subunit. Dose based loss in T NF-α and IL-2 release were observed in RBL-2H3 cells in addition to degranulation inhibition by CSB-0914. The compound demonstrated significant efficacy in reducing basophil activation assay induced by FcεRI receptors, with an IC50 value of 98.41 nM.. A dose dependent decrease in neutrophil migration and elastase were observed when treated with CSB- 0914. The compound was effective in decreasing. Upon stimulation, RBL-2H3 cells exhibited phosphorylation of NF-κB p-65 as well as upregulation of the Nrf2 and HO-1 signaling pathways. Collectively, our study has successfully identified a novel inhibitor called CSB-0914 that effectively regulates inflammatory responses. These reactions are primarily mediated by the interplay between NF-κB, Nrf2, and HO-1. The findings of this study provide support for the need to conduct more research on CSB-0914 with the aim of its development as a pharmaceutical agent for anti-inflammatory purposes.Communicated by Ramaswamy H. Sarma.
Gender differences in blood flow velocities after carotid angioplasty and stenting.

C. Timaran,G. Berdejo,T. Ohki,D. Timaran,F. Veith,E. Rosero,J. Modrall

DOI: https://doi.org/10.1016/J.AVSG.2007.04.003

IF: 1.5

2007-09-01

Annals of Vascular Surgery

Abstract:
scDrugPrio: a framework for the analysis of single-cell transcriptomics to address multiple problems in precision medicine in immune-mediated inflammatory diseases

Samuel Schäfer,Martin Smelik,Oleg Sysoev,Yelin Zhao,Desiré Eklund,Sandra Lilja,Mika Gustafsson,Holger Heyn,Antonio Julia,István A. Kovács,Joseph Loscalzo,Sara Marsal,Huan Zhang,Xinxiu Li,Danuta Gawel,Hui Wang,Mikael Benson

DOI: https://doi.org/10.1186/s13073-024-01314-7

IF: 15.266

2024-03-22

Genome Medicine

Abstract:Ineffective drug treatment is a major problem for many patients with immune-mediated inflammatory diseases (IMIDs). Important reasons are the lack of systematic solutions for drug prioritisation and repurposing based on characterisation of the complex and heterogeneous cellular and molecular changes in IMIDs.

genetics & heredity
Unveiling the Autoreactome: Proteome-wide Immunological Fingerprints Reveal the Promise of Plasma Cell Depleting Therapy.

Aaron Bodansky,David Jl Yu,Alysa Rallistan,Muge Kalaycioglu,Jim Boonyaratanakornkit,Damian J Green,Jordan Gauthier,Cameron J Turtle,Kelsey Zorn,Brian O'Donovan,Caleigh Mandel-Brehm,James Asaki,Hannah Kortbawi,Andrew F Kung,Elze Rackaityte,Chung-Yu Wang,Aditi Saxena,Kimberly de Dios,Gianvito Masi,Richard J Nowak,Kevin C O'Connor,Hao Li,Valentina E Diaz,Kaitlin B Casaletto,Eva Q Gontrum,Brandon Chan,Joel H Kramer,Michael R Wilson,Paul J Utz,Joshua A Hill,Shaun W Jackson,Mark S Anderson,Joseph L DeRisi

DOI: https://doi.org/10.1101/2023.12.19.23300188

2023-01-01

Abstract:The prevalence and burden of autoimmune and autoantibody mediated disease is increasing worldwide, yet most disease etiologies remain unclear. Despite numerous new targeted immunomodulatory therapies, comprehensive approaches to apply and evaluate the effects of these treatments longitudinally are lacking. Here, we leverage advances in programmable-phage immunoprecipitation (PhIP-Seq) methodology to explore the modulation, or lack thereof, of proteome-wide autoantibody profiles in both health and disease. We demonstrate that each individual, regardless of disease state, possesses a distinct set of autoreactivities constituting a unique immunological fingerprint, or "autoreactome", that is remarkably stable over years. In addition to uncovering important new biology, the autoreactome can be used to better evaluate the relative effectiveness of various therapies in altering autoantibody repertoires. We find that therapies targeting B-Cell Maturation Antigen (BCMA) profoundly alter an individual's autoreactome, while anti-CD19 and CD-20 therapies have minimal effects, strongly suggesting a rationale for BCMA or other plasma cell targeted therapies in autoantibody mediated diseases.
Abstract 90: In vitro functional evaluation of immuno-oncology drug candidates in customized bioassays

Martijn Vlaming,Emmanuelle Sidot,Jezabel Lefèvre,Ellen Boelen,Sofie Pattyn

DOI: https://doi.org/10.1158/1538-7445.am2024-90

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract Increased understanding of the complex tumor microenvironment and its interactors has boosted therapeutic interest and highlighted the importance of the development of innovative in vitro bioassays to represent all the players of the cancer immune response and thereby potentially provide pivotal information on the functional dynamics of candidate therapeutics. Regulatory T cells play an important role by downregulating the anti-tumor response. Their regulation mechanisms constitute an important target for new therapeutics. To study these mechanisms in a human model, suppressive Treg bioassays, mimicking the suppressive action of these cells, were developed and optimized. We further highlight the study of neutrophil function in vitro using flow-cytometry or the Incucyte® live imaging system to monitor neutrophil functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), Neutrophil Extracellular Traps (NETs) formation and the release of Reactive Oxygen Species (ROS). Additionally, multiplex cytokine and peroxidase enzyme analysis after activation and stimulation of neutrophils can be evaluated using ELISA or Luminex technology. Moreover, to refine/reduce non-human primate (NHP) usage, we aimed to develop cost-effective NHP in vitro assays with predictive value for in vivo studies. We isolated Cynomolgus Macaque monocytes and successfully differentiated/polarized them into M0- and M2-like macrophages with a cell surface phenotype comparable to that of their human counterparts. We further developed a Cynomolgus Macaque PBMC x human dendritic cell (DC) mixed lymphocyte reaction (MLR) assay for functional evaluation of test compounds, effectively generated Cynomolgus Macaque immature DCs and implemented Cynomolgus Macaque cytokine release assays.Using high quality primary human immune cells from our own biobank, in vitro bioassays have been developed with superior robustness and reproducibility to screen candidate Immuno-Oncology therapeutics. Citation Format: Martijn Vlaming, Emmanuelle Sidot, Jezabel Lefèvre, Ellen Boelen, Sofie Pattyn. In vitro functional evaluation of immuno-oncology drug candidates in customized bioassays [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 90.

oncology
A CRISPR-Cas9 delivery system for in vivo screening of genes in the immune system

Martin W. LaFleur,Thao H. Nguyen,Matthew A. Coxe,Kathleen B. Yates,Justin D. Trombley,Sarah A. Weiss,Flavian D. Brown,Jacob E. Gillis,Daniel J. Coxe,John G. Doench,W. Nicholas Haining,Arlene H. Sharpe

DOI: https://doi.org/10.1038/s41467-019-09656-2

IF: 16.6

2019-04-10

Nature Communications

Abstract:Therapies that target the function of immune cells have significant clinical efficacy in diseases such as cancer and autoimmunity. Although functional genomics has accelerated therapeutic target discovery in cancer, its use in primary immune cells is limited because vector delivery is inefficient and can perturb cell states. Here we describe CHIME: CHimeric IMmune Editing, a CRISPR-Cas9 bone marrow delivery system to rapidly evaluate gene function in innate and adaptive immune cells in vivo without ex vivo manipulation of these mature lineages. This approach enables efficient deletion of genes of interest in major immune lineages without altering their development or function. We use this approach to perform an in vivo pooled genetic screen and identify Ptpn2 as a negative regulator of CD8+ T cell-mediated responses to LCMV Clone 13 viral infection. These findings indicate that this genetic platform can enable rapid target discovery through pooled screening in immune cells in vivo.

multidisciplinary sciences

Pain in the early stages of orthodontic treatment.

High-Throughput Screening Platform for the Discovery of New Immunomodulator Molecules from Natural Product Extract Libraries

Data-driven discovery of innate immunomodulators via machine learning-guided high throughput screening

Immune cell screening of a nanoparticle library improves atherosclerosis therapy

Alterations in intracellular calcium during sepsis.

Using systems medicine to identify a therapeutic agent with potential for repurposing in inflammatory bowel disease

High-throughput screening identification of novel immunomodulatory combinations for the generation of tolerogenic dendritic cells

Abstract 2944: A high-throughput screening system for identifying therapeutic targets in immuno-oncology

Evaluating immune response in vitro in a relevant microenvironment: a high-throughput microfluidic model for clinical screening

A Computer Screening Approach to Immunoglobulin Superfamily Structures and Interactions: Discovery of Small Non-Peptidic CD4 Inhibitors As Novel Immunotherapeutics.

Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis

HLA-DR4 restricted lymphocyte proliferation to a Mycobacterium tuberculosis extract in rheumatoid arthritis and healthy subjects.

In silico Analyses of Immune System Protein Interactome Network, Single-Cell RNA Sequencing of Human Tissues, and Artificial Neural Networks Reveal Potential Therapeutic Targets for Drug Repurposing Against COVID-19

A novel bioinformatics pipeline for the identification of immune inhibitory receptors as potential therapeutic targets

High-throughput screening and in vitro evaluation of CSB-0914; a novel small molecule NF-κB inhibitor attenuating inflammatory responses through NF-κB, Nrf2 and HO-1 cross-talk

Gender differences in blood flow velocities after carotid angioplasty and stenting.

scDrugPrio: a framework for the analysis of single-cell transcriptomics to address multiple problems in precision medicine in immune-mediated inflammatory diseases

Unveiling the Autoreactome: Proteome-wide Immunological Fingerprints Reveal the Promise of Plasma Cell Depleting Therapy.

Abstract 90: In vitro functional evaluation of immuno-oncology drug candidates in customized bioassays

A CRISPR-Cas9 delivery system for in vivo screening of genes in the immune system